Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407990 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
A Phase 1 study of Advanced Cancer, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 451
- Enrollment target
- 20
- Study locations
NCT02407990: Completed Phase 1 study of Advanced Cancer, sponsored by BeiGene.
NCT02407990 is a Phase 1 study of Advanced Cancer that has completed, run by BeiGene. The registered enrollment target is 451 participants, above the 243-participant average among 122 other Advanced Cancer trials with a reported enrollment target (86% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02407990, a Phase 1 study of Advanced Cancer, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 451 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluated the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in participants with advanced tumors.
Primary Outcome
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product. All AEs were monitored per the National Cancer Institute Common
Conditions Studied
Interventions
- BIOLOGICAL BGB-A317
Study Locations (20)
Victoria
- Monash Health - Clayton
- Peter MacCallum Cancer Centre - East Melbourne
- Austin Health Hospital - Heidelberg
- Cabrini Hospital - Malvern
- Nucleus Network - Melbourne
- Royal Melbourne Hospital - Melbourne
Other
- Auckland City Hospital - Grafton
- Waikato - Hamilton
- Wellington Hospital - Wellington
- Seoul National University Hospital - Seoul
New South Wales
- Chris O'Brien Lifehouse - Camperdown
- Prince of Wales Hospital - Sydney
Queensland
- Tasman Oncology Research Ltd - Southport
- Princess Alexandra Hospital - Woolloongabba
South Australia
- Royal Adelaide Hospital - Adelaide
- The Queen Elizabeth Hospital - Woodville South
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- Oncology Consultants, P.A. - Houston
Western Australia
- Linear Clinical Research/Sir Charles Gairdner Hospital - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2020-08-12 |
| Phase | Phase 1 |
What the finished NCT02407990 record still lists
NCT02407990 is an interventional study that assigns participants to a tested intervention. The registered 451 participants enrollment target is mid-sized for trials with a published cap, above the 243-participant average among 122 other Advanced Cancer trials with a reported enrollment target (86% higher).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which BGB-A317 is the first listed.
NCT02407990 names 20 study sites across 9 states, led by Victoria, Other, New South Wales.
Frequently Asked Questions
What is clinical trial NCT02407990 about?
NCT02407990 is a clinical study titled "Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors". This study evaluated the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in participants with advanced tumors.
What is the current status of trial NCT02407990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 451 participants. The study started on 2015-06-02. Estimated completion is 2020-08-12.
What conditions does trial NCT02407990 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT02407990?
The interventions under investigation include: BGB-A317 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02407990?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02407990 being conducted?
This trial has 20 study locations across Massachusetts, Texas, New South Wales, Queensland, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02407990's enrollment target sits among peer trials
451 10th of 122 higher than 113 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI